Merus/$MRUS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Merus
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Ticker
$MRUS
Sector
Primary listing
Employees
291
Headquarters
Website
Merus Metrics
BasicAdvanced
$6.8bn
-
-$5.36
1.06
-
Price and volume
Market cap
$6.8bn
Beta
1.06
52-week high
$97.14
52-week low
$33.19
Average daily volume
1.3m
Financial strength
Current ratio
7.972
Quick ratio
7.588
Long term debt to equity
1.233
Total debt to equity
1.589
Profitability
EBITDA (TTM)
-368.772
Gross margin (TTM)
36.99%
Net profit margin (TTM)
-673.31%
Operating margin (TTM)
-655.80%
Effective tax rate (TTM)
-3.06%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
-26.53%
Return on equity (TTM)
-51.57%
Valuation
Price to revenue (TTM)
111.736
Price to book
8.81
Price to tangible book (TTM)
8.83
Price to free cash flow (TTM)
-19.898
Free cash flow yield (TTM)
-5.03%
Free cash flow per share (TTM)
-4.471
Growth
Revenue change (TTM)
57.54%
Earnings per share change (TTM)
34.86%
3-year revenue growth (CAGR)
7.45%
10-year revenue growth (CAGR)
36.52%
3-year earnings per share growth (CAGR)
54.40%
10-year earnings per share growth (CAGR)
-0.81%
What the Analysts think about Merus
Analyst ratings (Buy, Hold, Sell) for Merus stock.
Merus Financial Performance
Revenues and expenses
Merus Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs